B. Riley raised the firm’s price target on Opus Genetics (IRD) to $10 from $9 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics initiated with an Outperform at Citizens
- Opus Genetics management to meet with Piper Sandler
- Opus Genetics Secures $155 Million Senior Note Financing
- Opus Genetics: Undervalued Gene Therapy Play on Upcoming Retinal Disease Data Catalysts
- Opus Genetics Shareholders Approve Governance and Capital Changes